Bladder cancer recurrence: Part II. What do I tell my patients about lifestyle changes and dietary supplements?

Current Opinion in Urology

Volumn 13, Issue 5, 2003, Pages 379-383

  Moyad, Mark A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Alternative medicine; Bladder cancer; Complementary medicine; Dietary supplements; Lifestyle changes; Prevention; Recurrence

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROBIOTIC AGENT; PYRIDOXINE; RETINOL; ZINC;

BLADDER CARCINOMA; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; DIARRHEA; DIET SUPPLEMENTATION; FLUID INTAKE; GARLIC; HUMAN; LIFESTYLE; MORBIDITY; NAUSEA; NONHUMAN; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; VITAMIN SUPPLEMENTATION;

DIETARY SUPPLEMENTS; HUMANS; NEOPLASM RECURRENCE, LOCAL; RISK REDUCTION BEHAVIOR; URINARY BLADDER NEOPLASMS;

EID: 0041760781     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200309000-00004     Document Type: Review

References (46)

1. World Health Organization. The world health report. Geneva, Switzerland: World Health Organization, 1997.
2. Ries LAG, Kosary CL, Hankey BF, et al., editors. Surveillance Epidemiology and End Results (SEER) cancer statistics review, 1973-1994. (NIH publication no. 97.2789). Bethesda, MD: National Cancer Institute; 1997.
3. Wynder EL, Goldsmith R. The epidemiology of bladder cancer: a second look. Cancer 1977; 40:1246-1268.
4. Case RA, Hosker ME, McDonald DB, Pearson JT. Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. I. The role of aniline, benzidine, alpha-naphthylamine, and beta-naphthylamine (1954). Br J Ind Med 1993; 50:389-411.
5. Leistikow BN, Smith WE. California's reductions in smoking and bladder cancer incidence: a success story [Abstract 117]. J Urol 2001; 165:28.
6. Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 1982; 127:250-252.
7. Zlotta AR, Sohulman CC. Biological response modifiers for the treatment of superficial bladder tumors. Eur Urol 2000; 37:10-15.
8. Kim JC, Steinberg GD. The limits of bacillus Calmette-Guérin for carcinoma in situ of the bladder. J Urol 2001; 165:745-756.
9. Michaud DS, Spiegelman D, Clinton SK, et al. Fluid intake and the risk of bladder cancer in men. N Engl J Med 1999; 340:1390-1397.
10. Jones PA, Ross RK. Prevention of bladder cancer. N Engl J Med 1999; 340:1424-1426.
11. Donat SM, Katz JB, Herr HW. Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer [Abstract 790]. J Urol 2001; 165:191.
12. Thompson IM, Peek M, Rodriguez FR. The impact of cigarette smoking on stage, grade and number of recurrences of transitional cell carcinoma of the bladder. J Urol 1987; 137:401-403.
13. Aveyard P, Adab P, Cheng KK, et al. Does smoking status influence the prognosis of bladder cancer? A systematic review. BJU Int 2002; 90:228-239. One of the best overall literature reviews on the impact of smoking on the prognosis of bladder cancer. Most past studies suggest that smoking after a diagnosis can negatively impact prognosis.
14. Aso Y, Akaza H, and the BLP Study Group. Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. Urol Int 1992; 49:125-129.
15. Aso Y, Akaza H, Kotake T, et al. Prevention effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. Eur Urol 1995; 27:104-109.
16. Lim BK, Mahendran R, Lee YK, Bay BH. Chemopreventive effect of Lactobacillus rhamnosus on growth of a subcutaneously implanted bladder cancer cell line in the mouse. Jpn J Cancer Res 2002; 93:36-41.
17. Cremonini F, Di Caro S, Nista EC, et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002; 16:1461-1467.
18. Saavedra JM. Clinical applications of probiotic agents. Am J Clin Nutr 2001; 73 (Suppl.):1147S-1151S.
19. Kalliomaki M, Salminen S, Arvilommi H, et al. Probiotics in primary prevention of atopic disease: a randomized placebo-controlled trial. Lancet 2001; 357:1076-1079.
20. Jacobs EJ, Henion AK, Briggs PJ, et al. Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women. Am J Epidemiol 2002; 156:1002-1110.
21. Lamm DL, Riggs DR, Shriver JS, et al. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 1994; 151:21-26.
22. EORTC GU Group. Results of a prospective, randomized phase III study. Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Eur Urol 1995; 27:110-116.
23. Byar D, Blackard C. Comparisons of placebo, pyridoxine and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology 1977; 10:556-560.
24. Sindhwani P, Hampton JA, Baig MM, et al. Curcumin prevents intravesical tumor implantation of the MBT-2 tumor cell line in C3H mice. J Urol 2001; 166:1498-1501.
25. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21:2895-2900.
26. Kamat AM, Lamm DL. Chemoprevention of bladder cancer. Urol Clin North Am 2002; 29:157-168. An excellent overview of some of the latest chemoprevention agents for bladder cancer risk/recurrence prevention. An important primer to the world of chemoprevention and bladder cancer.
27. Marsh CL, Torrey RR, Woolley JL, et al. Superiority of intravesical immunotherapy with Corynebacterium parvum and Allium sativum in control of murine bladder cancer. J Urol 1987; 137:359-362.
28. Riggs DR, DeHaven JI, Lamm DL. Allium sativum (garlic) treatment for murine transitional cell carcinoma. Cancer 1997; 79:1987-1994.
29. Moon DG, Cheon J, Yoon DH, et al. Allium sativum potentiates suicide gene therapy for murine transitional cell carcinoma. Nutr Cancer 2000; 38:98-105.
30. Fleischauer AT, Arab L. Garlic and cancer: a critical review of the epidemiologic literature. J Nutr 2001; 131 (Suppl.):1032S-1040S.
31. Fleischauer AT, Poole C, Arab L. Garlic consumption and cancer prevention: meta-analyses of colorectal and stomach cancers. Am J Clin Nutr 2000; 72:1047-1052.
32. Ang-Lee MK, Moss J, Yuan C-S. Herbal medicines and perioperative care. JAMA 2001; 286:208-216.
33. Waddell WR, Longhry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24:83-87.
34. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in patients with familial adenomatous polyposis. Gastroenterology 1991; 101:635-639.
35. Giardello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328:1313-1316.
36. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121:241-246.
37. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk for colorectal cancer in women. N Engl J Med 1995; 333:609-614.
38. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348:891-899.
39. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107:1183-1188.
40. Steinbach G, Lynch P, Phillips M, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342:1946-1952.
41. Mohammed SI, Craig BA, Mutsaers AJ, et al. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol Cancer Ther 2003; 2:183-188.
42. Shariat SF, Kim JH, Ayala GE, et al. Cyclooxygenase. 2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol 2003; 169:938-942.
43. Kim SI, Kwon SM, Kim YS, Hong SJ. Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology 2002; 60:816-821.
44. Sweeney CJ, Marshall MS, Barnard DS, et al. Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. Cancer Detect Prev 2002; 26:236-244.
45. Hara S, Kondo Y, Matsuzawa I, et al. Expression of cyclooxygenase-2 in human bladder and renal cell carcinoma. Adv Exp Med Biol 2002; 507:123-126.
46. Castelao JE, Yuan JM, Gago-Dominguez M, et al. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000; 82:1364-1369.